Overview
Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerings, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities.
Emmanuelle Trombe is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is highly recommended for her expertise in the pharmaceutical, health care, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded. She has been distinguished as among the top 30 French business lawyers of 2020 and ranked among the foremost top French legal practitioners in the technology sector.
Results
- Advised Pierre Fabre on its exclusive collaboration and license agreement with Scorpion Therapeutics, Inc. for the co-development of certain epidermal growth factor receptor inhibitors
- Advised Innate Pharma SA on an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates with a primary focus in Celiac disease
- Advised Corteria Pharmaceuticals on an exclusive license agreement with Sanofi SA in respect of two cardiovascular assets designed to treat some types of heart failure
- Represented Innate Pharma on its global co-development and commercialization agreement with AstraZeneca for IPH2201, a novel antibody in Phase II development for the treatment of cancer
- Represented Servier in connection with its strategic partnership with Intarcia Therapeutics. The transaction is one of the largest biotechnology partnership agreements outside the United States
- Represented Pierre Fabre on its collaboration and licensing agreement with Array Biopharma for the development and commercialization of two novel oncology products, Binimetinib and Encorafenib
- Represented DBV Technologies on its US$281.5 million offering on NASDAQ
- Represented DBV on its collaboration agreement with Nestlé Health Science for the development and commercialization of a novel diagnostic test for pediatric milk allergy
- Represented Arterial Remodeling Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation
Recognitions
- Best Lawyers in France, ‘Lawyer of the Year’ in Biotechnology and Life Sciences, 2021-2024
- Chambers Europe, , Band 1, Pharma/Life Sciences (France): Emmanuelle is recommended for her expertise in “commercial, corporate and regulatory matters in the industry of healthcare and medical devices.” She was described as: “very knowledgeable in pharma, bio-technology and licensing agreements. She is very business-oriented and also described as “pragmatic, efficient and an outstanding negotiator.” 2014-2023
- The Legal 500 EMEA, Leading Individual in France: Healthcare and Life Sciences, 2022-2023
- IFLR1000, M&A, 2022-2023
Community
- Médecins sans Frontières, regularly provides contractual advice to this international humanitarian medical association
